Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street. Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $26.4 million. That equals 45¢ per share on sales of $264 million for the three […]
Wall Street Beat
Medtronic Diabetes to submit patch pump to FDA by fall 2026, separation remains on track
Medtronic officials today said the planned separation of its Diabetes business (MiniMed) remains on track, with future offerings also on the horizon. On the company’s second-quarter earnings call, CFO Thierry Piéton outlined the expected timelines for the Diabetes business, following another quarter of significant growth. Global Diabetes revenues grew 10.3% year over year, despite a […]
Tandem stock rises after hours on Q3 beats, record sales
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of TNDM rose nearly 20% to $15.89 apiece in post-market trading today. The San Diego-based automated insulin delivery technology developer reported losses of $21.2 million. That equals 31¢ per share on sales […]
Insulet leadership talks patch pump competition, expanding type 2 diabetes market
As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries could be on the way. The Acton, Massachusetts–based company’s Omnipod platform has long been the leader in the patch pump space, with the latest-generation Omnipod 5 delivering nearly $700 million in revenue in the company’s recently announced […]
Insulet increases guidance again on Q3 beats, 30% sales uptick
Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $87.6 million. That equals $1.24 per share on sales of $706.3 million […]
Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast. Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $19.5 million. That equals 43¢ per share on sales of $8.1 million for […]
Dexcom leadership addresses G7 issue claims, hopes for expanded CGM coverage
Amid some scrutiny over its latest-generation G7 continuous glucose monitor (CGM), Dexcom (Nasdaq:DXCM) officials addressed claims on the company’s latest earnings call. A recent class action lawsuit brought G7 into the spotlight, demanding a jury trial for claims that Dexcom’s representations for G7 were false, misleading, and deceptive to consumers. The lawsuit says G7 places […]
CGM market report: Significant growth is ahead
As millions of people worldwide seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow rapidly. Medtech market analysts project significant growth for the market over the next five years. Chrystal Larsen, a veteran medtech market analyst, produced a detailed report for MassDevice outlining the future of the CGM market. The report covers […]
Dexcom stock is down after hours despite Q3 beats, raised sales guidance
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of DXCM fell more than 8% to $62.69 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $283.8 million. That equals 70¢ per share on sales […]
Beta Bionics stock rises on Q3 beats, raised full-year guidance, advances iLet offerings
Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of BBNX rose around 20% to $29 apiece in post-market trading today. The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of […]
